233 related articles for article (PubMed ID: 25893522)
1. Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling.
Golden D; Saria EA; Hansen MF
J Cell Physiol; 2015 Dec; 230(12):2951-60. PubMed ID: 25893522
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
3. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells.
Beristain AG; Narala SR; Di Grappa MA; Khokha R
J Cell Sci; 2012 Feb; 125(Pt 4):943-55. PubMed ID: 22421365
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin activates osteosarcoma cells that co-express RANK and RANKL.
Marley K; Bracha S; Seguin B
Exp Cell Res; 2015 Oct; 338(1):32-8. PubMed ID: 26254896
[TBL] [Abstract][Full Text] [Related]
5. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
6. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
7. Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain.
Kusumi A; Sakaki H; Kusumi T; Oda M; Narita K; Nakagawa H; Kubota K; Satoh H; Kimura H
J Bone Miner Metab; 2005; 23(5):373-81. PubMed ID: 16133687
[TBL] [Abstract][Full Text] [Related]
8. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2.
Nadiminty N; Lou W; Lee SO; Mehraein-Ghomi F; Kirk JS; Conroy JM; Zhang H; Gao AC
Clin Cancer Res; 2006 Mar; 12(5):1420-30. PubMed ID: 16533764
[TBL] [Abstract][Full Text] [Related]
10. Osteoclast regulation of osteoblasts via RANK‑RANKL reverse signal transduction in vitro.
Zhang S; Wang X; Li G; Chong Y; Zhang J; Guo X; Li B; Bi Z
Mol Med Rep; 2017 Oct; 16(4):3994-4000. PubMed ID: 28731168
[TBL] [Abstract][Full Text] [Related]
11. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
13. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
[TBL] [Abstract][Full Text] [Related]
14. Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins.
Lai TH; Fong YC; Fu WM; Yang RS; Tang CH
Prostate; 2008 Sep; 68(12):1341-53. PubMed ID: 18512729
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
[TBL] [Abstract][Full Text] [Related]
16. Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway.
Huh JE; Lee WI; Kang JW; Nam D; Choi DY; Park DS; Lee SH; Lee JD
J Nat Prod; 2014 Nov; 77(11):2423-31. PubMed ID: 25397676
[TBL] [Abstract][Full Text] [Related]
17. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
[TBL] [Abstract][Full Text] [Related]
18. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
19. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
20. Estradiol protects against ethanol-induced bone loss by inhibiting up-regulation of receptor activator of nuclear factor-kappaB ligand in osteoblasts.
Chen JR; Haley RL; Hidestrand M; Shankar K; Liu X; Lumpkin CK; Simpson PM; Badger TM; Ronis MJ
J Pharmacol Exp Ther; 2006 Dec; 319(3):1182-90. PubMed ID: 16971503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
